Tom van der Poll Selected Research

lipopolysaccharide-binding protein

3/2006	Pulmonary lipopolysaccharide (LPS)-binding protein inhibits the LPS-induced lung inflammation in vivo.
8/2005	Lipopolysaccharide binding protein-deficient mice have a normal defense against pulmonary mycobacterial infection.
12/2004	Non-mannose-capped lipoarabinomannan induces lung inflammation via toll-like receptor 2.
11/2004	LPS-binding protein-deficient mice have an impaired defense against Gram-negative but not Gram-positive pneumonia.
12/2003	Lipopolysaccharide binding protein is an essential component of the innate immune response to Escherichia coli peritonitis in mice.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Tom van der Poll Research Topics

Disease

169	Sepsis (Septicemia) 10/2022 - 01/2002
156	Infections 12/2022 - 02/2002
132	Pneumonia (Pneumonitis) 12/2022 - 01/2002
123	Inflammation (Inflammations) 12/2022 - 04/2002
40	Pneumococcal Pneumonia 01/2021 - 01/2002
33	Endotoxemia 12/2020 - 04/2002
32	Critical Illness (Critically Ill) 01/2022 - 01/2004
25	Melioidosis 09/2020 - 04/2006
21	Peritonitis 01/2022 - 10/2003
19	Lung Injury 12/2020 - 10/2006
15	Human Influenza (Influenza) 01/2021 - 06/2004
14	Tuberculosis (Tuberculoses) 10/2017 - 01/2002
13	Acute Lung Injury 04/2013 - 05/2003
12	Asthma (Bronchial Asthma) 01/2021 - 04/2012
12	Disseminated Intravascular Coagulation 01/2017 - 12/2002
10	Hemorrhage 01/2022 - 08/2003
10	Respiratory Distress Syndrome (Acute Respiratory Distress Syndrome) 01/2021 - 05/2007
10	Shock 11/2020 - 12/2005
9	Bacterial Pneumonia 01/2022 - 03/2004
9	Fibrosis (Cirrhosis) 01/2021 - 03/2005
8	COVID-19 07/2022 - 10/2020
8	Bacterial Infections (Bacterial Infection) 01/2022 - 02/2006
8	Ventilator-Induced Lung Injury 12/2020 - 03/2009
8	Septic Shock (Toxic Shock Syndrome) 10/2020 - 04/2006
8	Necrosis 01/2017 - 03/2006
7	Pulmonary Fibrosis (Fibrosing Alveolitis) 06/2022 - 02/2014
7	Pneumococcal Infections 01/2021 - 01/2002
7	Hyperglycemia 10/2017 - 06/2006
7	Ischemia 01/2017 - 05/2004
7	Pneumococcal Meningitis (Streptococcus pneumoniae Meningitis) 06/2014 - 04/2003
6	HIV Infections (HIV Infection) 01/2017 - 04/2002
6	Hyperinsulinism (Hyperinsulinemia) 01/2011 - 06/2006
5	Thrombosis (Thrombus) 01/2019 - 01/2007
5	Pulmonary Tuberculosis 10/2017 - 08/2003
5	Malaria 01/2016 - 11/2004

Drug/Important Bio-Agent (IBA)

100	CytokinesIBA 12/2022 - 01/2002
43	Proteins (Proteins, Gene)FDA Link 01/2021 - 04/2003
42	Biomarkers (Surrogate Marker)IBA 10/2022 - 03/2008
40	LipopolysaccharidesIBA 01/2022 - 04/2002
38	AnticoagulantsIBA 01/2022 - 05/2003
34	ChemokinesIBA 01/2021 - 01/2002
31	Protein CIBA 01/2022 - 06/2003
29	Thrombin FDA Link 01/2022 - 05/2002
25	Interleukin-6 (Interleukin 6)IBA 12/2022 - 01/2002
24	Anti-Bacterial Agents (Antibiotics)IBA 01/2022 - 05/2003
22	FibrinIBA 01/2020 - 12/2002
21	Tumor Necrosis Factor-alpha (Tumor Necrosis Factor)IBA 01/2022 - 05/2002
19	Messenger RNA (mRNA)IBA 01/2021 - 05/2003
19	Toll-Like Receptors (Toll-Like Receptor)IBA 01/2017 - 12/2004
19	AntithrombinsIBA 09/2015 - 06/2004
16	Thromboplastin (Tissue Factor)IBA 01/2019 - 06/2004
16	Receptor for Advanced Glycation End ProductsIBA 01/2016 - 05/2007
15	Complement System Proteins (Complement)IBA 01/2021 - 07/2007
15	Hemostatics (Antihemorrhagics)IBA 01/2017 - 05/2002
13	Peptide Hydrolases (Proteases)FDA Link 01/2021 - 01/2004
12	Biological ProductsIBA 01/2022 - 08/2008
11	LigandsIBA 01/2021 - 03/2005
11	lipoteichoic acidIBA 01/2019 - 05/2002
10	Granzymes (Granzyme)IBA 07/2022 - 04/2014
10	EndotoxinsIBA 01/2017 - 06/2003
10	Toll-Like Receptor 4IBA 04/2015 - 08/2002
9	Interleukin-1 Receptors (Interleukin 1 Receptor)IBA 06/2022 - 02/2002
9	InterleukinsIBA 06/2022 - 02/2002
9	Peroxidase (Myeloperoxidase)IBA 01/2022 - 08/2002
9	Nucleosomes (Nucleosome)IBA 10/2017 - 01/2011
9	Interleukin-18 (Interleukin 18)IBA 08/2014 - 01/2002
8	Dacarbazine (DIC)FDA LinkGeneric 11/2014 - 12/2002
8	Toll-Like Receptor 2IBA 07/2014 - 03/2004
7	Bleomycin (Blenoxane)FDA LinkGeneric 06/2022 - 02/2014
7	AllergensIBA 01/2021 - 03/2013
7	Ceftriaxone (Ceftriaxon)FDA LinkGeneric 01/2019 - 07/2003
7	Interleukin-10 (Interleukin 10)IBA 05/2017 - 04/2003
7	Plasminogen InactivatorsIBA 01/2016 - 06/2006
6	Phosphotransferases (Kinase)IBA 01/2022 - 07/2009
6	Hydroxyproline (4 Hydroxyproline)IBA 01/2021 - 03/2005
6	ThrombomodulinIBA 01/2019 - 10/2005
6	Glucose (Dextrose)FDA LinkGeneric 10/2017 - 06/2006
6	AntigensIBA 01/2017 - 11/2005
6	Insulin (Novolin)FDA Link 08/2016 - 06/2006
6	platelet activating factor receptorIBA 06/2012 - 08/2003
6	Fibrin Fibrinogen Degradation ProductsIBA 10/2011 - 01/2009
6	Chemotactic FactorsIBA 12/2007 - 05/2002
5	Immunomodulating AgentsIBA 10/2022 - 01/2002
5	Oxygen (Dioxygen)IBA 06/2022 - 06/2009
5	Virulence Factors (Pathogenicity Factors)IBA 01/2021 - 01/2002
5	von Willebrand FactorIBA 09/2020 - 02/2014
5	antithrombin III-protease complexIBA 01/2019 - 06/2006
5	InflammasomesIBA 01/2018 - 03/2011
5	InterferonsIBA 07/2017 - 11/2004
5	p38 Mitogen-Activated Protein KinasesIBA 05/2017 - 04/2002
5	CoagulantsIBA 01/2017 - 10/2005
5	Prednisolone (Predate)FDA LinkGeneric 01/2016 - 02/2007
5	Antifibrinolytic Agents (Antifibrinolytics)IBA 01/2016 - 01/2010
5	Fibrinolysin FDA Link 01/2016 - 03/2004
5	Plasminogen Activator Inhibitor 1IBA 01/2016 - 12/2006

Therapy/Procedure

48	Therapeutics 10/2022 - 05/2003
18	Artificial Respiration (Mechanical Ventilation) 01/2022 - 10/2006
12	Critical Care (Surgical Intensive Care) 01/2022 - 01/2008
7	Intraperitoneal Injections 06/2010 - 06/2004
6	Ligation 04/2011 - 02/2004